BMRN vs. UTHR, ALNY, IONS, MDGL, ALKS, SRPT, VTRS, BGNE, LEGN, and APLS
Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include United Therapeutics (UTHR), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Viatris (VTRS), BeiGene (BGNE), Legend Biotech (LEGN), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical preparations" industry.
BioMarin Pharmaceutical vs.
BioMarin Pharmaceutical (NASDAQ:BMRN) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.
BioMarin Pharmaceutical has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
BioMarin Pharmaceutical received 970 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 75.17% of users gave BioMarin Pharmaceutical an outperform vote while only 60.59% of users gave United Therapeutics an outperform vote.
BioMarin Pharmaceutical presently has a consensus price target of $118.65, suggesting a potential upside of 20.16%. United Therapeutics has a consensus price target of $294.67, suggesting a potential upside of 35.65%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than BioMarin Pharmaceutical.
United Therapeutics has lower revenue, but higher earnings than BioMarin Pharmaceutical. United Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
United Therapeutics has a net margin of 36.76% compared to BioMarin Pharmaceutical's net margin of 3.30%. United Therapeutics' return on equity of 15.49% beat BioMarin Pharmaceutical's return on equity.
In the previous week, BioMarin Pharmaceutical and BioMarin Pharmaceutical both had 8 articles in the media. United Therapeutics' average media sentiment score of 1.12 beat BioMarin Pharmaceutical's score of 0.90 indicating that United Therapeutics is being referred to more favorably in the news media.
96.3% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 95.6% of United Therapeutics shares are owned by institutional investors. 1.8% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 12.5% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
United Therapeutics beats BioMarin Pharmaceutical on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioMarin Pharmaceutical Competitors List
Related Companies and Tools
